We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
-1.34%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$348M
AUM Growth
-$15.4M
Cap. Flow
+$604K
Cap. Flow %
0.17%
Top 10 Hldgs %
35.81%
Holding
95
New
24
Increased
19
Reduced
22
Closed
25

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$12.6M
2
PFE icon
Pfizer
PFE
+$11.1M
3
HOLX
Hologic
HOLX
+$9M
4
APLS
Apellis Pharmaceuticals
APLS
+$8.71M
5
LFST icon
Lifestance Health
LFST
+$6.74M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$12.1M
2
CYTK icon
Cytokinetics
CYTK
+$11M
3
ELV icon
Elevance Health
ELV
+$9.5M
4
SNY icon
Sanofi
SNY
+$9.22M
5
LHCG
LHC Group LLC
LHCG
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 97.71%
2 Energy 0%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COR icon
26
Cencora
COR
$63B
$4.78M 1.37%
40,000
-30,000
-43% -$3.6M
ALNY icon
27
Alnylam Pharmaceuticals
ALNY
$29.3B
$4.72M 1.36%
25,000
– –
AGL icon
28
Agilon Health
AGL
$1.51B
$4.72M 1.36%
7,200
+3,200
+80% +$2.73M
NTRA icon
29
Natera
NTRA
$45.8B
$4.46M 1.28%
40,000
-15,000
-27% -$1.72M
RLAY icon
30
Relay Therapeutics
RLAY
$4.42B
$4.41M 1.27%
140,000
+20,000
+17% +$673K
HRTX icon
31
Heron Therapeutics
HRTX
$59.9M
$4.38M 1.26%
410,000
+310,000
+310% +$3.77M
UHS icon
32
Universal Health Services
UHS
$9.96B
$4.15M 1.19%
30,000
-35,000
-54% -$5.3M
ARCT icon
33
Arcturus Therapeutics
ARCT
$212M
$4.06M 1.17%
+85,000
New +$3.81M
FOLD
34
DELISTED
Amicus Therapeutics
FOLD
$4.06M 1.17%
425,000
-50,000
-11% -$511K
EW icon
35
Edwards Lifesciences
EW
$53.6B
$3.96M 1.14%
35,000
-30,000
-46% -$3.42M
DNLI icon
36
Denali Therapeutics
DNLI
$4.02B
$3.78M 1.09%
75,000
-6,000
-7% -$338K
ABBV icon
37
AbbVie
ABBV
$440B
$3.77M 1.09%
+35,000
New +$4M
SIBN icon
38
SI-BONE Inc
SIBN
$849M
$3.64M 1.05%
170,000
+80,000
+89% +$2.02M
PTCT icon
39
PTC Therapeutics
PTCT
$6.17B
$3.61M 1.04%
97,100
-13,000
-12% -$534K
ATRA icon
40
Atara Biotherapeutics
ATRA
$80.1M
$3.58M 1.03%
+8,000
New +$2.87M
AVTX icon
41
Avalo Therapeutics
AVTX
$1.07B
$3.54M 1.02%
564
+330
+141% +$2.67M
MRTX
42
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.54M 1.02%
20,000
-30,000
-60% -$4.83M
RETA
43
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$3.52M 1.01%
35,000
-7,000
-17% -$821K
NVRO
44
DELISTED
NEVRO CORP.
NVRO
$3.49M 1%
30,000
-8,000
-21% -$1.05M
MGNX icon
45
MacroGenics
MGNX
$253M
$3.35M 0.96%
+160,000
New +$3.85M
ACRS icon
46
Aclaris Therapeutics
ACRS
$871M
$3.33M 0.96%
185,000
+10,000
+6% +$160K
AERI
47
DELISTED
Aerie Pharmaceuticals
AERI
$2.85M 0.82%
250,000
-160,000
-39% -$2.34M
BHVN
48
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$2.78M 0.8%
+20,000
New +$2.5M
INSM icon
49
Insmed
INSM
$29.3B
$2.75M 0.79%
+100,000
New +$2.62M
REPL icon
50
Replimune Group
REPL
$1.17B
$2.67M 0.77%
90,000
– –
1
2
3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q3 2021 Portfolio in Review

As of Q3 2021, Integral Health Asset Management held 95 positions worth $348M, down 4.2% from $363M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Integral Health Asset Management's Q3 2021 filing shows 24 new, 19 increased, 22 reduced and 25 closed positions. Its largest new stake was CVS Health: 150,000 shares worth $12.7M. The largest sale was Biogen, an estimated $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 93% a quarter earlier, followed by Energy and Industrials.

  • Integral Health Asset Management's largest Q3 2021 buy was CVS Health: 150,000 shares worth $12.7M.
  • Integral Health Asset Management added most to Apellis Pharmaceuticals in Q3 2021, an estimated $8.71M increase.
  • Integral Health Asset Management's biggest Q3 2021 reduction was Cytokinetics, cutting an estimated $11M.
  • Integral Health Asset Management fully exited Biogen in Q3 2021, selling an estimated $12.1M.
  • Integral Health Asset Management's ten largest holdings make up 36% of its $348M portfolio in Q3 2021.
  • Integral Health Asset Management opened 24 new positions and closed 25 in Q3 2021.
  • Integral Health Asset Management's portfolio value fell 4.2% quarter-over-quarter to $348M.

Based on Integral Health Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.